Unknown

Dataset Information

0

The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C.


ABSTRACT: BACKGROUND:A dinucleotide variant rs368234815 in interferon lambda 4 (IFNL4) gene was recently found to be associated with the hepatitis C virus (HCV) treatment response. This study aimed to assess the impact of IFNL4 rs368234815 polymorphism on treatment response to pegylated-IFN alpha (Peg-IFN-?) and ribavirin (RBV) in hemophilic patients with chronic hepatitis C (CHC). MATERIALS AND METHODS:In this retrospective study, 92 hemophilic patients with CHC who were treated with Peg-IFN-?/RBV were investigated. Single-nucleotide polymorphisms (SNPs) in IFNL genomic region including rs368234815, rs12979860, and rs8099917 were analyzed by DNA sequencing. RESULTS:Of the 92 patients, 63 (68.5%) achieved sustained virological response (SVR). Of the 43 patients with rs368234815 TT/TT genotype, 36 (83.7%) achieved SVR, while in 49 patients with non-TT/TT genotypes, 27 (55.1%) achieved SVR. Other pretreatment parameters predicted SVR were patients' body mass index, HCV genotype, rs12979860, and rs8099917 SNPs. In multivariate analysis, all above-mentioned parameters except rs8099917 remained as predictors of SVR. IFNL4 rs368234815 was a strong predictor of SVR; however, the prediction power of this SNP was the same as that of rs12979860 SNP in the patients of the current study. CONCLUSION:IFNL4 rs368234815 SNP can be considered for decision-making in the treatment of HCV-infected patients.

SUBMITTER: Keshvari M 

PROVIDER: S-EPMC5122234 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature

altmetric image

Publications

The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C.

Keshvari Maryam M   Alavian Seyed Moayed SM   Behnava Bita B   Pouryasin Ali A   Sharafi Heidar H  

Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences 20160901


<h4>Background</h4>A dinucleotide variant rs368234815 in interferon lambda 4 (<i>IFNL4</i>) gene was recently found to be associated with the hepatitis C virus (HCV) treatment response. This study aimed to assess the impact of <i>IFNL4</i> rs368234815 polymorphism on treatment response to pegylated-IFN alpha (Peg-IFN-α) and ribavirin (RBV) in hemophilic patients with chronic hepatitis C (CHC).<h4>Materials and methods</h4>In this retrospective study, 92 hemophilic patients with CHC who were trea  ...[more]

Similar Datasets

| S-EPMC4385537 | biostudies-literature
| S-EPMC3513206 | biostudies-other
| S-EPMC4000504 | biostudies-literature
| S-EPMC3229481 | biostudies-literature
| S-EPMC4428701 | biostudies-literature
| S-EPMC4282353 | biostudies-literature
| S-EPMC3695611 | biostudies-literature
| S-EPMC3296607 | biostudies-literature
| S-EPMC8771741 | biostudies-literature
| S-EPMC4042733 | biostudies-literature